ERBB2 and breast carcinoma: For locally-advanced, HER2-overexpressing breast cancer, docetaxel + trastuzumab-based neoadjuvant chemotherapy has been shown to achieve promising efficacy, with a good pathological complete response (pCR) rate, while being well tolerated in women with stage II or III HER2-positive breast cancer [1,2].